Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TL, de Leeuw BH, Zwarthoff EC, Teunisse A, van der Spek PJ, Klijn JG, Dinjens WN, Ethier SP, Clevers H, Jochemsen AG, den Bakker MA, Foekens JA, Martens JW, Schutte M. Hollestelle A, et al. Among authors: foekens ja. Breast Cancer Res Treat. 2010 May;121(1):53-64. doi: 10.1007/s10549-009-0460-8. Epub 2009 Jul 11. Breast Cancer Res Treat. 2010. PMID: 19593635
Subtypes of breast cancer show preferential site of relapse.
Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW. Smid M, et al. Among authors: foekens ja. Cancer Res. 2008 May 1;68(9):3108-14. doi: 10.1158/0008-5472.CAN-07-5644. Cancer Res. 2008. PMID: 18451135
CHEK2 1100delC and male breast cancer in the Netherlands.
Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M. Wasielewski M, et al. Among authors: foekens ja. Breast Cancer Res Treat. 2009 Jul;116(2):397-400. doi: 10.1007/s10549-008-0162-7. Epub 2008 Aug 31. Breast Cancer Res Treat. 2009. PMID: 18759107
MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer.
Rodríguez-González FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V, Sleijfer S, Martens JW, Foekens JA. Rodríguez-González FG, et al. Among authors: foekens ja. Breast Cancer Res Treat. 2011 May;127(1):43-51. doi: 10.1007/s10549-010-0940-x. Epub 2010 May 19. Breast Cancer Res Treat. 2011. PMID: 20490652
411 results